Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Abstract

Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.

Keywords

SemaglutideType 2 diabetesMedicineDiabetes mellitusInternal medicineCardiologyEndocrinology

MeSH Terms

AdministrationOralAgedCardiovascular DiseasesDiabetes MellitusType 2Double-Blind MethodFemaleGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsMaleMiddle AgedRiskGlucagon-Like Peptide-1 Receptor Agonists

Affiliated Institutions

Related Publications

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies , David A. D’Alessio , Judith Fradkin +7 more

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on...

2018 Diabetes Care 3378 citations

Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus

Jerrold M. Olefsky , Orville Kolterman , J A Scarlett

Resistance to the action of insulin can result from a variety of causes, including the formation of abnormal insulin or proinsulin molecules, the presence of circulating antagon...

1982 American Journal of Physiology-Endocr... 277 citations

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray , Scott D. Solomon , Silvio E. Inzucchi +35 more

BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through ...

2019 New England Journal of Medicine 6238 citations

Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction

Klas Malmberg , Anna Norhammar , Hans Wedel +1 more

Background —The Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study addressed prognostic factors and the effects of concomitant treatment and gly...

1999 Circulation 851 citations

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus

K. Malmberg

Insulin-glucose infusion followed by intensive subcutaneous insulin in diabetic patients with acute myocardial infarction improves long term survival, and the effect seen at one...

1997 BMJ 1299 citations

Publication Info

Year: 2019
Type: article
Volume: 381
Issue: 9
Pages: 841-851
Citations: 1708
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1708

OpenAlex

Influential

1495

CrossRef

Cite This

APA Style

                            
                                
                                    Mansoor Husain, 
                                
                                    Andreas L. Birkenfeld, 
                                
                                    Morten Donsmark
                                
                                et al.
                            
                            (2019). 
                            Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. 
                            New England Journal of Medicine
                            , 381
                            (9)
                            , 841-851.
                            https://doi.org/10.1056/nejmoa1901118
                        

Identifiers

DOI: 10.1056/nejmoa1901118
PMID: 31185157

Data Quality

Data completeness: 90%